Cargando…
Atezolizumab plus platinum-based regimen and bevacizumab: is it time to consider immunotherapy in a concurrent approach for lung cancer?
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
AME Publishing Company
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8797422/ https://www.ncbi.nlm.nih.gov/pubmed/35117074 http://dx.doi.org/10.21037/tcr.2018.11.06 |
| _version_ | 1784641549131317248 |
|---|---|
| author | Bianco, Andrea Campbell, Susan F. M. |
| author_facet | Bianco, Andrea Campbell, Susan F. M. |
| author_sort | Bianco, Andrea |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8797422 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2019 |
| publisher | AME Publishing Company |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-87974222022-02-02 Atezolizumab plus platinum-based regimen and bevacizumab: is it time to consider immunotherapy in a concurrent approach for lung cancer? Bianco, Andrea Campbell, Susan F. M. Transl Cancer Res Editorial AME Publishing Company 2019-03 /pmc/articles/PMC8797422/ /pubmed/35117074 http://dx.doi.org/10.21037/tcr.2018.11.06 Text en 2019 Translational Cancer Research. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/. |
| spellingShingle | Editorial Bianco, Andrea Campbell, Susan F. M. Atezolizumab plus platinum-based regimen and bevacizumab: is it time to consider immunotherapy in a concurrent approach for lung cancer? |
| title | Atezolizumab plus platinum-based regimen and bevacizumab: is it time to consider immunotherapy in a concurrent approach for lung cancer? |
| title_full | Atezolizumab plus platinum-based regimen and bevacizumab: is it time to consider immunotherapy in a concurrent approach for lung cancer? |
| title_fullStr | Atezolizumab plus platinum-based regimen and bevacizumab: is it time to consider immunotherapy in a concurrent approach for lung cancer? |
| title_full_unstemmed | Atezolizumab plus platinum-based regimen and bevacizumab: is it time to consider immunotherapy in a concurrent approach for lung cancer? |
| title_short | Atezolizumab plus platinum-based regimen and bevacizumab: is it time to consider immunotherapy in a concurrent approach for lung cancer? |
| title_sort | atezolizumab plus platinum-based regimen and bevacizumab: is it time to consider immunotherapy in a concurrent approach for lung cancer? |
| topic | Editorial |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8797422/ https://www.ncbi.nlm.nih.gov/pubmed/35117074 http://dx.doi.org/10.21037/tcr.2018.11.06 |
| work_keys_str_mv | AT biancoandrea atezolizumabplusplatinumbasedregimenandbevacizumabisittimetoconsiderimmunotherapyinaconcurrentapproachforlungcancer AT campbellsusanfm atezolizumabplusplatinumbasedregimenandbevacizumabisittimetoconsiderimmunotherapyinaconcurrentapproachforlungcancer |